TITLE

Clinical Relevance and Cost-Savings of Levocarnitine Versus Ammonul in the Management Of Hyperammonemia in a Cancer Patient: The Impact of a Clinical Pharmacist

AUTHOR(S)
Anyanwu, Chukwuma; Ezeudu, Chinonso; Hoa Le; Egwim, Oliver; Le, Hoa
PUB. DATE
January 2018
SOURCE
P&T: A Peer-Reviewed Journal for Managed Care & Formulary Manage;Jan2018, Vol. 43 Issue 1, p52
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
Background: Hyperammonemia, a relatively uncommon condition characterized by elevated ammonia levels in the blood, presents with varied physiological etiologies that may send patients to the intensive care unit (ICU) with encephalopathy. An immediate decrease in ammonia levels is necessary to avert neurological damage. However, due to the multifaceted nature of hyperammonemia, a definite determination of etiology is not always possible.Objective: This case report examines the clinical and economic impact of a pharmacist in managing acute hyperammonemia of unknown etiology in a 62-year-old Hispanic man who had recently been diagnosed with metastatic medullary thyroid cancer and associated hypercalcemia. The patient was treated with levocarnitine after the failure of several other treatments.Results: Levocarnitine therapy controlled the patient's ammonia levels, which had progressively reached extremely high levels. His mental status, which had deteriorated severely, returned to baseline.Conclusion: This case illustrates the importance of having a clinical pharmacist in the ICU. The pharmacist's expertise and knowledge helped avert adverse clinical consequences and promoted considerable cost-savings. This case also shows that levocarnitine may be an effective treatment for certain cases of hyperammonia-induced encephalopathy with unknown etiology.
ACCESSION #
127123379

 

Related Articles

  • Combo drug therapy promising for anaplastic thyroid cancer.  // Medical Device Daily;4/24/2013, Vol. 17 Issue 79, Special section p1 

    The article reports that researchers at the Mayo Institute in Jacksonville, Florida, have discovered a combo drug therapy of anti-proliferative paclitaxel and the PPAR-inhibiting efatutazone for anaplastic thyroid cancer.

  • Iodine-131.  // Reactions Weekly;2/11/2012, Issue 1388, p20 

    The article describes the clinical cases of two women, diagnosed with papillary thyroid carcinoma, who developed lacrimal duct obstruction after receiving iodine-131.

  • Prognosis of Patients with Papillary Thyroid Carcinoma Located in One Lobe Showing Lateral Node Metastasis in the Contralateral but Not Ipsilateral Compartment. Ito, Yasuhiro; Higashiyama, Takuya; Takamura, Yuuki; Kobayashi, Kaoru; Miya, Akihiro; Miyauchi, Akira // Journal of Thyroid Research;2012, p1 

    Papillary thyroid carcinoma (PTC) frequently metastasizes to the lymph node in lateral compartment, which can often be detected on preoperative ultrasonography (N1b). However, PTC located in one lobe showing contralateral but not ipsilateral N1b is not common. We analyzed the clinicopathological...

  • Thyroid Cancer:Molecular Aspects and New Therapeutic Strategies. Grande, Enrique; Díez, Juan José; Zafon, Carles; Capdevila, Jaume // Journal of Thyroid Research;2012, p1 

    Despite that thyroid cancer accounts for over 90% of tumors that arise from the endocrine system, these tumors barely represent 2% of solid tumors in adults. Many entities are grouped under the general term of thyroid cancer, and they differ in histological features as well as molecular and...

  • FDA Drug Approvals. New molecular entity.  // Formulary;Jul2011, Vol. 46 Issue 7, p247 

    The article reports on testing which the U.S. Food and Drug Administration conducted in 2011 on the drug vandetanib, an oral kinase inhibitor used to treat thyroid cancer, prior to approving the drug.

  • Primary Papillary Thyroid Carcinoma in The Thyroglossal Cyst. Akif Eryılmaz, Mehmet; Toy, Hatice // European Journal of General Medicine;2011, Vol. 8 Issue 1, p69 

    Papillary thyroid carcinoma within the thyroglossal duct cyst is a very rare finding and its presentation is like the benign cyst. A 22 years old female patient with a midline neck mass was initially diagnosed thyroglossal duct cyst and underwent Sistrunks procedure and upon histopathologic...

  • Case Report. Metastatic Papillary Thyroid Carcinoma Masked by Diffuse Parenchymal Calcification. Karaköse, Melia; Topaloğlu, Oya; Demirci, Taner; Arslan, Müyesser Sayki; Özbek, Mustafa; Şahin, Mustafa; Delibaşı, Tuncay // Turkish Journal of Endocrinology & Metabolism;Mar2014, Vol. 18 Issue 1, p17 

    A patient with papillary thyroid carcinoma most commonly presents with a thyroid nodule or cervical lymphadenopathy. The ultrasonographic features of malign nodules are well known by the clinicians. Incidentally diagnosed papillary carcinomas are frequently microcarcinomas and it is believed...

  • Papillary Thyroid Cancer, Macrofollicular Variant: The Follow-Up and Analysis of Prognosis of 5 Patients. Erol, Varlik; Makay, Özer; Ertan, Yeçim; İçöz, Gökhan; Akyildiz, Mahir; Yilmaz, Mustafa // Journal of Thyroid Research;2014, p1 

    Objective. The main aim of this study was to comparatively analyze the recurrence and prognosis of this rare variant with the literature by analyzing the follow-up data of 5 patients diagnosed with papillary cancer macrofollicular variant. Methods. The demographic data, radiological and...

  • Value of Thyroid Incidentalomas on Positron Emission Tomographic Scans among Thyroidectomy Patients. Amir, Alexander; Karls, Shawn; Sands, Noah; Forest, Véronique-Isabelle; Hier, Michael; Gologan, Olga; Payne, Richard // Journal of Otolaryngology -- Head & Neck Surgery;Oct2011, Vol. 40 Issue 5, p391 

    Objectives: To evaluate the preoperative predictive value of a positive positron emission tomographic (PET) scan with respect to malignancy in future thyroidectomy candidates, particularly when the fine-needle aspiration biopsy (FNAB) results in indeterminate findings, and to establish the...

  • The Effects of the Factors Related to the Patient and the Disease on the Performance of Ablation Therapy in Patients with Differentiated Thyroid Cancer who have Received I-131 Ablation Therapy. Seng�z, Tarik; S�r�c�, Erdem; Demir, Yusuf; Derebek, Erkan // Molecular Imaging & Radionuclide Therapy;Oct2012, Vol. 21 Issue 3, p103 

    To investigate whether the factors related to the patient and the disease have any effect on the success of ablation therapy in patients with differentiated thyroid cancer who have received I-131 ablation therapy. Material and Methods: All the patients with differentiated thyroid cancer were...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics